Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy

You may be eligible if

• pathologically diagnosed as malignant melanoma, HMB45 (+～++++), S100 (+～++++);
• Basically normal hepatic and renal functions as well as results for blood routine examinations;
• Karnofsky score ≥ 60;
• Anticipated life span for more than three months;
• They were all malignant melanoma patients suffering from skin malignant melanoma of local or distal metastasis unsuitable for operations in their skin;
• The therapeutic efficacy was objectively evaluated with reference to the criteria from WHO;
• All of the subjects had signed the informed consent and had been submitted and approved by the ethic committee of the hospital, the compliance was good and follow-ups can be easily carried out.